Lessons from my bad trade in INCY call options in my Volatility Portfolio
Wow. That sure didn’t work the way I intended. Back on May 23 I added the July 21 $140 calls on Incyte (INCY) to my Volatility Portfolio. Those calls traded at $7.10 that day. As I wrote in my post that day, to make money on these options, I’d need to get a move of $4 or so to move the share price above $140 and to move the options into the money. My logic at the time was pretty simple.
Nervous market has been hard on Nektar; hold options in my Volatility Portfolio for September news (and beyond)
Biotechs--and indeed any high price-to-earnings stocks perceived as risky--have taken more than their share of punishment in the nervous sell off of the last few weeks. Nektar Therapeutics (NKTR), for example, closed yesterday August 21 at $17.79. That's down from...
Drug stocks like what the Trump administration is saying about regulating drug prices
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Adding Incyte call options to my Volatility Portfolio on short-term news flow
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Incyte up on positive trial results
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Trump’s pick to head the FDA is a friend to the drug industry, but he’s not likely to be equally friendly to all types of drug company
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Sell Bristol-Myers Squibb before Thursday’s earnings report
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Worse than expected: 24 million people would lose health insurance by 2026, CBO estimates
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Incyte pops big again on buy out rumors again–hold on for the rest of the ride
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Ionis gets hit hard in biotech pullback
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Merck writes off $2.9 billion it spent on hepatitis C drug purchased in 2014; here’s who to watch in the biotech sector after this news
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...Jim’s Stock Alerts
Download Jim’s eBook for Free
